Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigné, Hervé Dombret, Thierry de Revel et al.|The Lancet|2012Cited by 994
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic LeukemiaPierre Fenaux, Laurent Degos, Claude Chastang et al.|Blood|1999Cited by 745
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Claude Preudhomme, Hervé Dombret, C. Sagot et al.|Blood|2002Cited by 503
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 StudyCécile Pautas, Sylvie Castaigné|Journal of Clinical Oncology|2010Cited by 217